FDA rejects Unicycive and Sobi filings over contract manufacturing deficiencies
Unicycive Therapeutics and Sobi received complete response letters for kidney disease and gout filings, respectively, after the FDA found fault with their manufacturing partners.
FDA rejects Unicycive and Sobi filings over contract manufacturing deficiencies Read More »
